- Home
- ZUMZ vs VRXA Comparison
ZUMZ vs VRXA Comparison
Compare ZUMZ & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZUMZ | VRXA |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.2M | 263.0M |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ZUMZ | VRXA |
|---|---|---|
| Price | $13.95 | $1.44 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 304.8K | ★ 390.5K |
| Earning Date | 06-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $929,057,000.00 | N/A |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.48 | N/A |
| 52 Week Low | $13.07 | $1.27 |
| 52 Week High | $31.70 | $4.50 |
Technical Indicators
Market Signals| Indicator | ZUMZ | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 37.54 |
| Support Level | N/A | $1.27 |
| Resistance Level | $18.87 | $1.99 |
| Average True Range (ATR) | 0.68 | 0.17 |
| MACD | -0.35 | 0.01 |
| Stochastic Oscillator | 16.90 | 27.30 |
Price Performance
Historical ComparisonAbout ZUMZ Zumiez Inc.
Zumiez Inc is a United States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art, action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.